HealthcareServices

Diabetic Retinopathy Market Forecast 2026–2035: How to Leverage Market Growth

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the diabetic retinopathy market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Diabetic Retinopathy Market be in 2030 compared with 2026?

The diabetic retinopathy market has experienced substantial growth in recent years. Projections indicate it will expand from $9.26 billion in 2025 to $9.97 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. This historical growth can be attributed to factors such as increasing diabetes prevalence, late diagnosis of retinal damage, limited screening access, a rise in vision impairment cases, and a dependence on hospital-based eye care.

The diabetic retinopathy market is projected to experience substantial expansion over the next few years, with its size anticipated to reach $13.54 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. This growth during the forecast period is attributed to the rise of AI-assisted screening tools, the expansion of ophthalmology clinics, increasing adoption of anti-VEGF therapy, a heightened focus on preventive eye care, and a growing aging diabetic population. Major trends foreseen for this period include the rising adoption of retinal screening programs, increased utilization of anti-VEGF therapies, the expansion of early detection and monitoring capabilities, the growing integration of AI-based retinal imaging, and an elevated focus on vision preservation.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12187&type=smp

What Drivers Are Guiding Growth Patterns In The Diabetic Retinopathy Market?

The increasing occurrence of diabetes is anticipated to propel the expansion of the diabetic retinopathy market. Diabetes is characterized as a long-term metabolic condition resulting in high blood glucose levels. The surge in diabetes prevalence is largely influenced by factors such as overweight status, obesity, genetic predispositions, and insufficient physical activity. Patients with diabetes often have elevated sugar concentrations in their blood, which can damage the retina—the part of the eye that senses light and transmits signals to the brain through a nerve located at the back of the eye. For instance, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government department, revealed that between March 2022 and March 2023, the proportion of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, it rose by 21%. Moreover, the percentage of people achieving target HbA1c levels reached 37.9%, marking the highest figure ever recorded by the National Diabetes Audit. Therefore, the growing prevalence of diabetes is a significant driver for the diabetic retinopathy market.

Which Segments Are Driving Activity In The Diabetic Retinopathy Market?

The diabetic retinopathy market covered in this report is segmented –

1) By Type: Proliferative Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy

2) By Treatment: Anti-VEGF Drugs, Intraocular Steroid Injection, Laser Photocoagulation, Vitreoretinal Surgery

3) By End-User: Hospitals, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Proliferative Diabetic Retinopathy (PDR): Neovascularization, Vitreous Hemorrhage, Tractional Retinal Detachment

2) By Non-Proliferative Diabetic Retinopathy (NPDR): Mild NPDR, Moderate NPDR, Severe NPDR

Which Trends Are Guiding The Evolution Of The Diabetic Retinopathy Market?

Leading companies operating within the diabetic retinopathy market are strategically focusing on partnerships to enhance their profitability. Partnerships in this field signify collaborative endeavors between diverse stakeholders, such as healthcare providers, researchers, pharmaceutical companies, and advocacy groups, all aimed at addressing the complexities linked to diabetic retinopathy. As an illustration, in October 2023, AEYE Health, a US-based company specializing in AI-driven diagnostics for retinal imaging, formed a collaboration with Topcon Screen, a Japan-based platform for diabetic screening. The primary objective of their collaboration is to implement artificial intelligence-based point-of-care screening for diabetic retinopathy, ensuring swift and precise results, which empowers primary care clinicians to conduct these screenings directly within their clinics. This method is designed to mitigate non-compliance risks and bridge existing care gaps related to diabetic retinopathy screening by providing immediate and accurate assessments at the point of care.

Which Major Firms Are Strengthening Their Position In The Diabetic Retinopathy Market?

Major companies operating in the diabetic retinopathy market are Pfizer Inc., F-Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Regeneron Pharmaceuticals Inc., Allergan plc., Genentech Inc., Santen Pharmaceutical Co Ltd., Carl Zeiss Meditec AG, Lumenis Ltd., Optos Plc., Quantel Medical SAS, NIDEK Co Ltd., IRIDEX Corporation, Alimera Science Inc., Oxurion NV, EyePoint Pharmaceuticals, Opthea Limited, KalVista Pharmaceuticals Inc., Regenxbio Inc., Kodiak Sciences Inc., Oculis, Verseon International Corporation, Clearside Biomedical Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Diabetic Retinopathy Market?

North America was the largest region in the diabetic retinopathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic retinopathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Diabetic Retinopathy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12187&type=smp

Browse Through More Reports Similar to the Global Diabetic Retinopathy Market 2026, By The Business Research Company

Diabetic Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Non Proliferative Diabetic Retinopathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report

Proliferative Diabetic Retinopathy Pdr Market Report 2026

https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795